Long-Term Liver Disease, Treatment, and Mortality Outcomes Among 17,000 Persons Diagnosed with Chronic Hepatitis C Virus Infection

• Autores: Anne C. Moorman, Loralee B. Rupp, Stuart C. Gordon, Yuna Zhong, Jian Xing, Mei Lu, Joseph A. Boscarino, Mark A. Schmidt, Yihe G. Daida, Eyasu H. Teshale, Philip R. Spradling, Scott D. Holmberg
• Localización: Infectious disease clinics of North America, ISSN 0891-5520, Vol. 32, Nº. 2, 2018 (Ejemplar dedicado a: Overcoming Barriers to Eliminate Hepatitis C), págs. 253-268
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Chronic Hepatitis Cohort Study (CHeCS) publications using data from “real-world” patients with hepatitis C virus (HCV) have described demographic disparities in access to care; rates of advanced liver disease, morbidity, and mortality (2.5%–3.5% per year during 2006–10, although only 19% of all CHeCS decedents, and just 30% of those with deaths attributed to liver disease, had HCV listed on death certificate); substantial comorbidities, such as diabetes, advanced liver fibrosis (29% prevalence), renal disease, and depression, and partial reversal of all these with successful antiviral therapy; patient risk behaviors; and use of noninvasive markers to assess liver disease.